Stockscreener 앱 받기
6.60
0.76%
0.05
전일 마감가:
$6.55
열려 있는:
$6.55
하루 거래량:
660.04K
Relative Volume:
0.45
시가총액:
$498.63M
수익:
$11.40B
순이익/손실:
$-95.73M
주가수익비율:
-2.6939
EPS:
-2.45
순현금흐름:
$-64.37M
1주 성능:
+7.32%
1개월 성능:
+20.88%
6개월 성능:
-14.95%
1년 성능:
-23.70%
1일 변동 폭
$6.5123
$6.74
1주일 범위
$6.16
$6.74
52주 변동 폭
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
명칭
Mind Medicine Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
MNMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.60 | 464.65M | 11.40B | -95.73M | -64.37M | -2.45 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Mind Medicine Inc 주식(MNMD)의 최신 뉴스
Was Jim Cramer Right About Mind Medicine (MNMD) Stock? - Insider Monkey
(MNMD) Technical Data - news.stocktradersdaily.com
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? - MSN
MindMed to Present at the 2025 RBC Capital Markets Global Health - GuruFocus
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Joplin Globe
MindMed projects 2026 trial readouts for pivotal MM120 studies in GAD and MDD - MSN
MindMed to Host Key Opinion Leader Webinar on Substance Use Diso - GuruFocus
Mind Medicine (MNMD) Rating and Price Target Maintained by Chard - GuruFocus
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance - insights.citeline.com
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... - Yahoo Finance
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... By GuruFocus - Investing.com Canada
MindMed Advances Phase 3 Trials for Brain Health - TipRanks
Transcript : Mind Medicine Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
MindMed Advances Phase 3 Trials for Brain Health Treatments - TipRanks
MindMed Q1 2025 slides: Phase 3 trials advance as cash position remains strong - Investing.com Australia
Earnings call transcript: MindMed Q1 2025 results show mixed signals By Investing.com - Investing.com Australia
Earnings call transcript: MindMed Q1 2025 results show mixed signals - Investing.com
MindMed (MNMD) Advances Phase 3 Trials with Growing Enthusiasm | - GuruFocus
Mind Medicine (MindMed) Inc. SEC 10-Q Report - TradingView
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates - Business Wire
(MNMD) Long Term Investment Analysis - news.stocktradersdaily.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 | MNMD Stock News - GuruFocus
Great week for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) institutional investors after losing 28% over the previous year - simplywall.st
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Yahoo Finance
Mind Medicine (Mindmed) IncMindmed Enters Into First Amendment To Loan And Security AgreementSEC Filing - marketscreener.com
MindMed Announces New Employee Inducement Grants | MNMD Stock Ne - GuruFocus
MindMed Announces New Employee Inducement Grants | MNMD Stock News - GuruFocus
MindMed Announces New Employee Inducement Grants - Business Wire
Lobbying Update: $100,000 of MIND MEDICINE (MINDMED) INC. lobbying was just disclosed - Nasdaq
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
How the (MNMD) price action is used to our Advantage - news.stocktradersdaily.com
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
Mind Medicine Inc (MNMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mind Medicine Inc 주식 (MNMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Karlin Daniel | Chief Medical Officer |
Mar 25 '25 |
Sale |
6.74 |
6,836 |
46,075 |
446,177 |
| Sullivan Mark | Chief Legal Officer |
Mar 25 '25 |
Sale |
6.74 |
6,576 |
44,322 |
316,621 |
| Liao Carrie | Chief Accounting Officer |
Mar 25 '25 |
Sale |
6.74 |
2,347 |
15,819 |
144,923 |
1.54%
7.58%
자본화:
|
볼륨(24시간):